The phase 2 MAGNIFY trial demonstrated that zervimesine (CT1812) slowed lesion growth in patients with geographic atrophy secondary to dry AMD, showing a 28.6% reduction over 18 months.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 9, 2025.

Catch up on any of the neurology news headlines you may have missed over the course of April 2025, compiled all into one place by the NeurologyLive® team.

Over long-term treatment, fenfluramine significantly reduced seizure frequency, increased seizure-free days, and improved quality of life in patients with Dravet syndrome.

A study involving 20 patients with ALS found that longitudinal muscle MRI detected progressive atrophy and correlated with muscle strength loss, supporting its potential as a biomarker for ALS progression and clinical trials.

Evan L. Smith, PhD, assistant professor of Physical Medicine & Rehabilitation at University of Michigan, discussed how emotional wellbeing, motivation, and evidence-based therapies can significantly influence outcomes in MS.

Leveraging the Enroll-HD dataset, recent data revealed consistent links between antidopaminergic medication use and worsened cognitive and motor outcomes in Huntington disease.

Early findings from the ASPIRO trial showed ANPD001 was safe, well-tolerated, and led to marked improvements in motor symptoms and daily functioning.

STN-FUS provided more sustained tremor reduction, improved bradykinesia, and had a higher responder rate at 12 months, though both treatments showed comparable reductions in rigidity and motor scores.

A 17-year-old with NMOSD and rituximab treatment developed PML after several relapses and secondary hypogammaglobulinemia, leading to his death 3 months after diagnosis.

The research portfolio director at the Muscular Dystrophy Association highlighted advances in gene-targeted therapies and biomarker development as potential key drivers of progress in ALS.

Theranica's FDA-cleared, drug-free migraine device gains expanded access, more than doubling coverage to 80 million Americans as young as 8 years old who are diagnosed with migraine.

Sunny Brous, a patient advocate living with ALS, shared how her decade-long journey with the disease shaped her mission to build connection, advocate for change, and empower the ALS community.

Baron, a neurologist and headache specialist at Cleveland Clinic, explained the significance, clinical data, and patient potential behind CT-132, the first FDA-approved digital therapeutic for migraine prevention.

Capricor Therapeutics reported that it remains on track for PDUFA target action date of August 31, 2025 and noted that advisory committee meeting is to be held in advance.

The award ceremony is supported by Viatris and will take place on Thursday, May 29, 2025, at the Phoenix Convention Center in Phoenix, Arizona, during the 2025 CMSC Annual Meeting.

New 24-month data further showed dose-dependent lowering of neurofilament light and trends on major end points such as cUHDRS, Total Function Capacity, and Symbol Digit Modalities Test.

Over a 4-week treatment period, daridorexant outperformed placebo on several subjective sleep and nocturia assessments, while maintaining a good safety and tolerability profile.

The expanded access program enables the collection of real-world data on the safety and efficacy of SPG302, which may support its clinical development for the treatment of amyotrophic lateral sclerosis.

Here's some of what is coming soon to NeurologyLive® this week.

Christine Greiss, DO, medical director for the Center for Brain injuries at Hackensack Meridian Health, discussed the nuanced impact of hormonal fluctuations, psychological factors, and postmenopausal status on TBI recovery in women.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the Peripheral Nerve Society annual meeting.

Nexalin plans to submit a Q-Submission to the FDA for its Gen-2 SYNC system, aiming to advance trials for Alzheimer disease, dementia, and mild cognitive impairment following positive internal data and FDA feedback.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 2, 2025.

Jack P. Antel, MD, professor of neurology and neurosurgery at McGill University, reflected on key advances in neuroimmune research and their implications for understanding and treating MS.